

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERGE— United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/974,519	10/10/2001	Dhiren R. Thakker	421/32/2	7285
	7590 04/21/2004		EXAMINER	
JENKINS & WILSON, PA 3100 TOWER BLVD			WEBMAN, EDWARD J	
SUITE 1400	SUITE 1400		ART UNIT	PAPER NUMBER
DURHAM, N	NC 27707		1617	
* .			DATE MAILED: 04/21/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE MAILED:

FIRST NAMED APPLICANT ATTY. DOCKET NO. APPLICATION NUMBER FILING DATE 09/974519 EXAMINER ART UNIT PAPER NUMBER 3/20/04

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS					
OFFICE ACTION SUMMARY					
Responsive to communication(s) filed on					
☐ This action is FINAL .					
Since this application is in condition for allowance except for formal matters, prosecut accordance with the practice under <i>Ex parte Quayle</i> , 1935 D.C. 11; 453 O.G. 213.	ion as to the merits is closed in				
A shortened statutory period for response to this action is set to expire	the period for response will cause				
Disposition of Claims					
Claim(s)	is/are pending in the application.				
Of the above, claim(s) $4-5$, 7 , $9-27$	is/are withdrawn from consideration.				
Claim(s)	is/are allowed.				
Claim(s)	is/are objected to.				
Claim(s)are	subject to restriction or election requirement.				
Application Papers					
See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed onis/are objecte The proposed drawing correction, filed on The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner.	d to by the Examineris				
Priority under 35 U.S.C. § 119					
Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).					
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents h	ave been				
received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule)					
*Certified copies not received:	<u>. </u>				
Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
Attachment(s)					
Notice of Reference Cited, PTO-892					
Information Disclosure Statement(s), PTO-1449, Paper No(s).					
☐ Interview Summary, PTO-413	•				
Notice of Draftperson's Patent Drawing Review, PTO-948					
Notice of Informal Patent Application, PTO-152					
	MACES				

-- SEE OFFICE ACTION ON THE FOLLOWING PAGES--

Application/Control Number: 09/974,519

Art Unit: 1617

Applicant's election of intestinal epithelium in Paper No. 6/10/03 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-3, 6, 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liu et al in view of Wissner et al '045.

Applicants stipulate that Wissner '045 teach synthesis of phosphocholines (page 17 lines 20-24). However, Wissner '045 further teaches orally administered phosphocholine derivatives (column 43 lines 29-55).

Applicants further stipulate alkylphosphocholines are known in the art as inhibitors of phospholipase C (page 18 lines 1-7).

Liu et al teach an alkyl phosphocholine for enhancement of Para cellular permeability to overcome the barrier to absorption of orally administered hydrophilic drugs posed by tight junctions in the intestinal epithelium.

It would have been obvious to one of ordinary skill to enhance permeability of tight Junctions in the intestinal epithelium with Alkyl phosphocholines for the beneficial effect of overcoming the barrier to absorption of orally administered hydrophilic drugs in view of Liu et al. As to the claimed oral administration, Wissner et al '045 teach oral

Application/Control Number: 09/974,519

Art Unit: 1617

delivery of such phosphocholine derivatives. As to the claimed property of inhibition of phospholipase C, applicants stipulate such is known in the art.

Applicants argue that Liu et al does not teach the inhibition of permeability by inhibition of phospholipase C.

However, applicants stipulate that it is known in the art that alkyl phosphocholines are known phospholipase C inhibitors. Therefore, one of ordinary skill would expect the correction demonstrated by applicants given Liu et al s' work.

No claims allowed.

Any inquiry concerning this communication should be directed to Edward J. Webman at telephone number 571-272-0633.

Webman/tgd

March 23, 2004

EDWARD I. WEBMAN PRIMARY EXAMINER GROUP 1500